This is a professional authority, a profession that is respected and welcomed by doctors. However, because of the rebates and sales of gold, people are labeled as “low-level” and “profiteering”. When it comes to medical representatives, people are always smashed.

At the end of 2016, CCTV reported on the “rebate door incident”, and some medical representatives used the “envelope” to send doctors a rebate. The report mentioned that the medical representative received a commission of 10% of the price of the drug, while the doctor received a rebate of 30%-40% of the price of the drug. Subsequently, some localities have successively introduced relevant measures. Some provincial health planning commissions have again requested that sales personnel not be allowed to enter the medical treatment area to engage in drug sales activities such as drugs and equipment. Medical personnel are not allowed to receive sales promotion from sales personnel in the medical treatment area.

On March 23, 2017, the General Office of the State Council issued the Notice of the General Office of the State Council on Printing and Distributing the Main Points of Public Affairs Work in 2017, and regarded the “opening of information on the registration and filing of medical representatives” as the main point of work of the State Council in 2017. Recently, “Building a more standardized and more valuable clinical academic exchange system for the Chinese pharmaceutical industry and a seminar on the registration and filing system for medical representatives” was held in Beijing. At the meeting, Pan Guangcheng, president of the China Chemical Pharmaceutical Industry Association, also revealed that the registration system for medical representatives has been explicitly included in the newly revised Drug Administration Law.

How can we make medical representatives become a popular occupation among doctors, how can we change the abnormal relationship between doctors and medical representatives? Some scholars believe that in fact, the best time for China's pharmaceutical industry and pharmaceutical companies to abandon drug rebates and establish a compliance marketing system has arrived.

Ultra-high sales cost, drug rebate, hotbed

"In recent years, there have been some problems in the development of clinical academic exchanges in China. Academic exchanges are no longer simple, no longer clean, and even become an excuse for some enterprises to use commercial bribery as a marketing tool." When there are problems in the marketing system, Guo Yunpei, president of the China Pharmaceutical Enterprise Management Association, said, "It should be said that there are various reasons for this change, such as price, bidding, etc. But in any case, this change is for Chinese medicine. Both the medical industry and the medical industry have caused great harm. It has not only eroded the interaction between medicines, but also hindered the innovation and development of the pharmaceutical industry. More importantly, it also placed a heavy burden on the national medical insurance fund and taxation. Degraded the overall image of the industry."

Guo Yunpei said that since the launch of the new medical reform in 2009, the Party Central Committee and the State Council have proposed to abandon the use of medicine to raise medicine and squeeze out the water in the middle of medicines. "The capital cost of R&D in China's pharmaceutical companies is much lower than that of international multinational pharmaceutical companies for R&D. The R&D expenses of foreign innovative pharmaceutical companies can usually account for more than 10% of the company's sales revenue, but most pharmaceutical companies in China. This number is often below 5%. It is understood that China's pharmaceutical market share has accounted for 10%-11% of the global market, ranking second in the world, but less than 5% of our products are own brands. Moreover, it is a patented product, and more than 95% of the drugs are imitation products. In Guo Yunpei's view, this phenomenon has been caused by various reasons such as long approval period, insufficient R&D and innovation capability, fierce competition with the same disease type, and large market competition. At the same time, high sales expenses are also an important reason for the low R&D expenses.

In fact, the current cost of sales for pharmaceutical companies in China is very high, which is much higher than that of foreign countries. Guo Yunpei said, “In particular, it is estimated that the cost of selling gold will not be less.”

Immunization Using Cell Culture Based Rabies Vaccines

Rabies is a viral infection transmitted by saliva of infected mammals, most commonly wild, terrestrial carnivores (e.g., skunks, raccoons, foxes, coyotes) or bats.

Immunization Using Cell Culture Based Rabies Vaccines,Based Rabies Vaccines,Cell Culture Rabies Vaccines,Cell Culture Based Rabies Vaccines

Changchun Zhuoyi Biological Co., Ltd , https://www.zhuoyibiological.com